AARD Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. (AARD) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.73 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -8.5% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company's lead product candidate includes ARD-101. Aardvark Therapeutics Inc. is based in SAN DIEGO.
Sector
Healthcare
Industry
Biotechnology